Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that it has received a Drug Registration Certificate from China’s National Medical Products Administration (NMPA) for Vitamin K1 Injection (0.2 ml : 2 mg), a Chemical Drug Class 3 generic product indicated for the prevention and treatment of vitamin K deficiency bleeding (VKDB) in infants – making Easton the third domestic manufacturer to obtain approval for this pediatric specification with bioequivalence status against the originator product.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Certificate Type | Drug Registration Certificate |
| Certificate Number | 2026S03681 |
| Approval Number | 国药准字 H20266188 |
| Product | Vitamin K1 Injection |
| Specification | 0.2 ml : 2 mg |
| Registration Classification | Chemical Drug Class 3 (generic with bioequivalence) |
| Shelf Life | 18 months |
| MAH / Manufacturer | Easton Pharmaceutical Co., Ltd. |
| Originator / Reference Product | Konakion® MM (Cheplapharm Arzneimittel GmbH) |
| Bioequivalence Status | Deemed to have passed consistency evaluation (视同通过一致性评价) |
Drug Profile & Therapeutic Indications
- Molecule: Phytomenadione (Vitamin K1) – a fat‑soluble vitamin essential for hepatic synthesis of coagulation factors II, VII, IX, and X
- Formulation: Mixed micellar injection (glycocholic acid / phospholipid‑based drug‑carrying system) – the same formulation technology as the originator Konakion® MM, enabling safe intravenous, intramuscular, and subcutaneous administration
- Indication (0.2 ml : 2 mg – newly approved): Prevention and treatment of vitamin K deficiency bleeding (VKDB) in infants – a potentially life‑threatening hemorrhagic condition in newborns caused by physiological vitamin K deficiency at birth
- Indication (1 ml : 10 mg – previously approved, May 2026): Treatment of vitamin K deficiency bleeding and prevention of vitamin K deficiency in patients where nutritional supplementation is insufficient
- Clinical Significance: Vitamin K1 prophylaxis at birth is a universally recommended neonatal standard of care endorsed by the WHO, AAP, and Chinese pediatric guidelines, making this a high‑volume, essential medicine with stable institutional demand
Competitive Landscape – Vitamin K1 Injection in China
| Category | Details |
|---|---|
| Originator | Konakion® MM (Cheplapharm Arzneimittel GmbH); 0.2 ml:2 mg spec approved in China March 2026; 1 ml:10 mg spec previously approved |
| New‑Classification Generics (Bioequivalence‑Deemed) | Six companies including Hainan Beite, Hefei Yifan, Easton Pharmaceutical, and three others – all referencing Konakion® MM as the comparator |
| 0.2 ml:2 mg Spec Generics (Bioequivalence‑Deemed) | Three companies approved to date; Easton is the third |
| Old‑Classification Generics | Multiple additional manufacturers approved under legacy registration standards (not bioequivalence‑deemed) |
Easton’s dual‑specification strategy – with both 1 ml:10 mg (approved May 2026) and 0.2 ml:2 mg (approved October 2026) – provides comprehensive coverage across the adult and pediatric segments of the vitamin K1 injection market, positioning the company to compete across hospital formulary tiers and procurement categories.
Market Impact & Outlook
- Market Size: According to Menet (米内网) data from key provincial and city public hospitals, Vitamin K1 Injection generated approximately RMB 43.39 million (≈ US$6.1 million) in sales during the first half of 2026, implying a full‑year public hospital market in the range of RMB 80–90 million – a niche but stable essential‑medicine category with predictable institutional demand.
- Neonatal Prophylaxis Demand: Vitamin K1 administration at birth is a mandatory neonatal procedure in China’s maternity hospitals, ensuring a baseline demand tied to the annual birth cohort. The 0.2 ml:2 mg pediatric specification is the standard neonatal dose formulation, making it the higher‑volume specification in institutional procurement.
- Procurement Advantage: Bioequivalence‑deemed generics are treated as therapeutically equivalent to the originator in China’s centralized and provincial volume‑based procurement (VBP) systems, granting Easton eligibility for hospital formulary inclusion and government procurement tenders on equal footing with the originator.
- Dual‑Spec Commercial Platform: Holding approvals for both specifications enables Easton to bundle supply across adult and pediatric indications, an advantage in hospital tender evaluations that favor comprehensive product portfolios.
- Competitive Intensity: With six bioequivalence‑deemed generics already approved for at least one specification, the vitamin K1 injection market is becoming increasingly competitive. Easton’s third‑mover position in the pediatric spec is timely, as the market is still transitioning from old‑classification products to quality‑equivalent generics.
- Financial Impact: Easton stated that the approval will not have a material impact on near‑term financial performance, consistent with the niche market size. The strategic value lies in portfolio breadth and hospital channel access rather than standalone revenue contribution.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market adoption, and procurement potential of Vitamin K1 Injection in China. Drug registration approval does not guarantee commercial success. Actual outcomes may differ due to risks including volume‑based procurement pricing pressure, competitive dynamics, hospital formulary decisions, and changes in clinical guidelines or reimbursement policy.-Fineline Info & Tech
